Profile

Rebecca A. Gardner, MD

Rebecca A. Gardner, MD

Hematology-Oncology

On staff since July 2009

Academic Title: Acting Assistant Professor

Research Center: Ben Towne Center for Childhood Cancer Research

"I was drawn to the field of pediatric oncology because of the kids. It is an honor to be involved with patients and their families as we work toward curing their cancer."

Rebecca A. Gardner, MD, is an acting assistant professor in the Department of Pediatrics at the University of Washington, and attending physician at Seattle Children's Hospital.

Her research focuses on the development of immunotherapy trials for the treatment of pediatric leukemia and lymphoma. The immune system can be a powerful tool in the treatment and erradication of pediatric malignancies. From advances in the lab, we are now able to genetically modify a person's own T cells to allow the T cells to specifically recognize and kill cancer cells.

Making A Difference

  • Spearheading New Cancer Therapy

    Seattle Children’s takes a step toward revolutionizing the way cancer is treated with the hospital’s first reprogrammed T cell immunotherapy trial for relapsed leukemia.   ... cont.

Overview

Board Certification(s)

Pediatrics
Pediatric Hematology-Oncology

Medical/Professional School

University of Maryland School of Medicine - Deans Office, Baltimore

Residency

Pediatrics, University of Utah School of Medicine, Salt Lake City

Fellowship

Hematology, University of Washington School of Medicine, Seattle

Publications

  • Gardner RA, Thomson B, Hawkins DS
    Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity.
    Pediatric blood & cancer , 2012 Sept. 26
  • Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR
    Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
    Blood , 2012 Jan. 5 : 119(1)72-82
  • Rebecca A. Gardner, MD
    Disruption of Glucocorticoid Regulation in Therapeutic Human T Cells with Zinc Finger Nucleases
    Molecular Thearpy , 2010 : 18(S1)s240
  • Losick VP, Schlax PE, Emmons RA, Lawson TG
    Signals in hepatitis A virus P3 region proteins recognized by the ubiquitin-mediated proteolytic system.
    Virology , 2003 May 10 : 309(2)306-19
  • Azzam HS, DeJarnette JB, Huang K, Emmons R, Park CS, Sommers CL, El-Khoury D, Shores EW, Love PE
    Fine tuning of TCR signaling by CD5.
    Journal of immunology (Baltimore, Md. : 1950) , 2001 May 1 : 166(9)5464-72
  • DeJarnette JB, Sommers CL, Huang K, Woodside KJ, Emmons R, Katz K, Shores EW, Love PE
    Specific requirement for CD3epsilon in T cell development.
    Proceedings of the National Academy of Sciences of the United States of America , 1998 Dec. 8 : 95(25)14909-14

Research Funding

Grant Title Grantor Amount Award Date
A phase 1 trial of autologous T cells genetically modified to express a CD19 specific chimeric antigen receptor to treat pediatric relapsed acute lymphoblastic leukemia SCRI-CCTR Clinical Research Scholar Program May 2012 - May 2014
Autologous T cells Modified to Target CD19+ Pediatric ALL Rally Foundation May 2012 - May 2013
Engineering a Graft Versus Leukemia Effect into Cord Blood Transplant Alex's Lemonade Stand July 2011 - Sept. 2013